<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500617</url>
  </required_header>
  <id_info>
    <org_study_id>CDX_000004</org_study_id>
    <secondary_id>PREDICT</secondary_id>
    <nct_id>NCT00500617</nct_id>
  </id_info>
  <brief_title>Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>Identification of Gene Expression Patterns in Circulating Cells That Predict the Presence of Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioDx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene
      expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD). The Corus
      CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR (RT-PCR) to
      quantify the expression of multiple genes from circulating peripheral blood cells to assess
      the presence of clinically significant CAD in a patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the PREDICT study is to develop and validate a diagnostic blood ASGES (age,
      sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD).
      The Corus CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR
      (RT-PCR) to quantify the expression of multiple genes from circulating peripheral blood cells
      to assess the presence of clinically significant CAD in a patient.

      This is a prospective, multi-center, observational study. Participation in the study does not
      alter clinical care. The only procedure required by the protocol is collection of a research
      blood sample. All other data collected will be in accordance with each participating
      institution's standard patient care.

      The study is divided into four sequential segments with unique subjects and goals: ASGES
      (Corus CAD) discovery (segment 1), ASGES (Corus CAD) development (segment 2), ASGES (Corus
      CAD) validation (segment 3), and additional ASGES (Corus CAD) testing (segment 4). The
      primary analysis will be performed during the third segment of the study using a subset of
      the enrolled subjects (&quot;primary subjects&quot;). Primary subjects will be defined by additional
      eligibility criteria beyond the general eligibility criteria required for enrollment in the
      overall study. The additional, post-enrollment eligibility criteria will be based on clinical
      and demographic factors that are found during the course of the study to affect the
      expression of genes used in the ASGES (Corus CAD). Such factors will be identified during
      gene discovery and algorithm development. The post-enrollment eligibility criteria will be
      defined prior to the beginning of the ASGES (Corus CAD) validation segment of the study.

      In addition, three substudies are planned and will enroll up to 1500 subjects.

        -  The first substudy will include subjects undergoing cardiac CT angiography (CTA) and
           aims to determine how gene expression correlates with total coronary atheroma burden, as
           measured by CTA.

        -  The second substudy examines sample handling and shipping conditions and does not affect
           the treatment of the subjects.

        -  The third substudy will focus on additional algorithm development and validation in a
           non-diabetic female patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Algorithm AUC &gt;0.50</measure>
    <time_frame>30days</time_frame>
    <description>The primary analysis will be performed during the third segment of the study using a subset of the enrolled subjects (&quot;primary subjects&quot;). The primary endpoint for the PREDICT study is a validated algorithm that can accurately classify subjects with and without any coronary artery lesion with a â‰¥50% diameter stenosis, as measured by Core Laboratory blinded quantitative coronary angiography. In evaluating this endpoint, subjects will be classified as either cases or controls. The endpoint will be assessed by calculating the area under the curve (AUC) for the algorithm score, and testing against an AUC = 0.50 to determine clinical utility, using an alpha level of 0.05 (two-sided).</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">4350</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Chest Pain</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>CAD</condition>
  <condition>CVD</condition>
  <condition>CHD</condition>
  <arm_group>
    <arm_group_label>segment 1</arm_group_label>
    <description>Gene discovery blood draw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sement 2</arm_group_label>
    <description>Assay development blood draw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>segment 3</arm_group_label>
    <description>Assay validation blood draw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>segment 4</arm_group_label>
    <description>Additional assay testing blood draw (Note: post discovery diabetic subjects assigned to this group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Corus CAD (ASGES)</intervention_name>
    <description>Age/Sex/Gene Expression Score - ASGES</description>
    <arm_group_label>segment 1</arm_group_label>
    <arm_group_label>sement 2</arm_group_label>
    <arm_group_label>segment 3</arm_group_label>
    <arm_group_label>segment 4</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, buffy coat, spun plasma, RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing clinically indicated invasive coronary artery angiogram or CT
        angiogram.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referral for a coronary angiogram (either invasive X-ray angiography or coronary CTA)

          -  Any one of the following clinical syndromes:

               1. chest pain syndrome, stable angina, or anginal equivalent suggesting myocardial
                  ischemia

               2. low-risk unstable angin, or

               3. asymptomatic individuals with a high probability of CAD

        Exclusion Criteria:

          -  History of myocardial infarction or known CAD

          -  Current Myocardial Infarct (MI), acute coronary syndrome with high-risk features or
             unstable angina with high-risk features

          -  New York Heart Association (NYHA) class III or IV congestive

          -  Inability to give informed congestive heart failures

          -  Severe left ventricular systolic dysfunction (LVEF&lt;35%)

          -  Severe regurgitant or stenotic cardiac valve lesion

          -  Active or chronic systemic infection

          -  Rheumatologic, autoimmune or hematologic conditions

          -  Any organ transplant

          -  Immunosuppressive therapy

          -  Chemotherapy in the preceding year

          -  Major blood or blood product transfusion in the preceding 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Monane, MD FACP CMQ</last_name>
    <role>Study Chair</role>
    <affiliation>CardioDx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alaska Heart Institute</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CV Medical Group Southern California</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps HealthCare</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuqua Heart Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain HealthCare</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, Sager PT, Sehnert AJ, Yau M, Kraus WE, Newby LK, Schwartz RS, Voros S, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky A, Winn ME, Schork NJ, Topol EJ; PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree) Investigators. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med. 2010 Oct 5;153(7):425-34. doi: 10.7326/0003-4819-153-7-201010050-00005.</citation>
    <PMID>20921541</PMID>
  </results_reference>
  <results_reference>
    <citation>Voros S, Elashoff MR, Wingrove JA, Budoff MJ, Thomas GS, Rosenberg S. A peripheral blood gene expression score is associated with atherosclerotic Plaque Burden and Stenosis by cardiovascular CT-angiography: results from the PREDICT and COMPASS studies. Atherosclerosis. 2014 Mar;233(1):284-90. doi: 10.1016/j.atherosclerosis.2013.12.045. Epub 2014 Jan 20.</citation>
    <PMID>24529158</PMID>
  </results_reference>
  <results_reference>
    <citation>Beineke P, Fitch K, Tao H, Elashoff MR, Rosenberg S, Kraus WE, Wingrove JA; PREDICT Investigators. A whole blood gene expression-based signature for smoking status. BMC Med Genomics. 2012 Dec 3;5:58. doi: 10.1186/1755-8794-5-58.</citation>
    <PMID>23210427</PMID>
  </results_reference>
  <results_reference>
    <citation>Lansky A, Elashoff MR, Ng V, McPherson J, Lazar D, Kraus WE, Voros S, Schwartz RS, Topol EJ. A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) trial. Am Heart J. 2012 Sep;164(3):320-6. doi: 10.1016/j.ahj.2012.05.012. Epub 2012 Jul 24.</citation>
    <PMID>22980297</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, Voros S, Ellis SG, Waksman R, McPherson JA, Lansky AJ, Topol EJ; PREDICT Investigators. Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. J Cardiovasc Transl Res. 2012 Jun;5(3):366-74. doi: 10.1007/s12265-012-9353-z. Epub 2012 Mar 7.</citation>
    <PMID>22396313</PMID>
  </results_reference>
  <results_reference>
    <citation>Elashoff MR, Wingrove JA, Beineke P, Daniels SE, Tingley WG, Rosenberg S, Voros S, Kraus WE, Ginsburg GS, Schwartz RS, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky AJ, Topol EJ. Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Med Genomics. 2011 Mar 28;4:26. doi: 10.1186/1755-8794-4-26.</citation>
    <PMID>21443790</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2007</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Molecular Genetics</keyword>
  <keyword>Gene Expression</keyword>
  <keyword>GES</keyword>
  <keyword>CAD</keyword>
  <keyword>CVD</keyword>
  <keyword>CHD</keyword>
  <keyword>Clinical Validity</keyword>
  <keyword>Precision Medicine</keyword>
  <keyword>ASGES</keyword>
  <keyword>CT Angiography</keyword>
  <keyword>Corus CAD</keyword>
  <keyword>Coronary angiorgram</keyword>
  <keyword>Age/Sex/Gene expression Score</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Angina Pectoris</keyword>
  <keyword>Chest Pain</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>CTA</keyword>
  <keyword>PREDICT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

